Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BAYRYNASDAQ:ONCNASDAQ:SMMTOTCMKTS:SSDOY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBAYRYBayer Aktiengesellschaft$6.61+2.8%$6.07$4.79▼$8.58$25.98B0.93862,245 shs747,571 shsONCBeigene$244.90-4.4%$247.70$141.31▼$287.88$25.33B0.49491,171 shs488,142 shsSMMTSummit Therapeutics$23.47-36.0%$20.90$2.10▼$36.91$17.31B-0.463.76 million shs24.58 million shsSSDOYShiseido$16.75+2.6%$17.88$15.32▼$33.88$6.69B0.32107,266 shs16,043 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBAYRYBayer Aktiengesellschaft+2.88%+6.81%+1.42%+17.12%-11.43%ONCBeigene+2.82%+10.90%+2.27%+25,615,999,900.00%+25,615,999,900.00%SMMTSummit Therapeutics+10.30%+49.13%+81.32%+54.46%+922.28%SSDOYShiseido+1.75%-2.22%-16.01%-1.75%-40.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBAYRYBayer AktiengesellschaftN/AN/AN/AN/AN/AN/AN/AN/AONCBeigene3.1627 of 5 stars4.50.00.00.02.91.70.6SMMTSummit Therapeutics2.6308 of 5 stars4.51.00.00.03.21.70.0SSDOYShiseido1.0619 of 5 stars0.03.00.80.01.60.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBAYRYBayer Aktiengesellschaft 2.00HoldN/AN/AONCBeigene 3.00Buy$318.8830.21% UpsideSMMTSummit Therapeutics 3.00Buy$36.7056.37% UpsideSSDOYShiseido 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SSDOY, ONC, BAYRY, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025SMMTSummit TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$31.00 ➝ $44.004/24/2025ONCBeigeneTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/23/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/21/2025ONCBeigeneJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.004/7/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$312.004/7/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$312.003/26/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$35.003/26/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$23.00 ➝ $35.003/21/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBAYRYBayer Aktiengesellschaft$51.55B0.50$5.16 per share1.28$9.11 per share0.73ONCBeigene$3.81B6.35N/AN/A$37.10 per share6.60SMMTSummit Therapeutics$700K24,733.36N/AN/A$0.11 per share213.36SSDOYShiseido$6.55B1.02$1.62 per share10.34$11.31 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBAYRYBayer Aktiengesellschaft-$3.18B-$0.72N/A5.80N/A-2.02%16.90%4.94%5/13/2025 (Estimated)ONCBeigene-$881.71M-$6.14N/A344.937.73-25.94%-25.12%-14.95%N/ASMMTSummit Therapeutics-$614.93M-$0.31N/AN/AN/AN/A-85.42%-52.66%4/29/2025 (Estimated)SSDOYShiseido-$71.52M-$0.19N/A20.17N/A-1.10%-1.68%-0.82%5/9/2025 (Estimated)Latest SSDOY, ONC, BAYRY, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/ABAYRYBayer Aktiengesellschaft$0.48N/AN/AN/A$13.39 billionN/A4/29/2025Q1 2025SMMTSummit Therapeutics-$0.0715N/AN/AN/AN/AN/A2/27/2025Q4 2024ONCBeigene-$0.88-$1.43-$0.55-$1.43$1.09 billion$1.13 billion2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 million2/14/2025Q4 2024SSDOYShiseido$0.1733-$0.19-$0.3633-$0.19$1.72 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBAYRYBayer Aktiengesellschaft$0.020.30%N/AN/A N/AONCBeigeneN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ASSDOYShiseido$0.070.42%N/AN/A N/ALatest SSDOY, ONC, BAYRY, and SMMT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/22/2025BAYRYBayer Aktiengesellschaft$0.02240.38%4/29/20254/30/20255/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBAYRYBayer Aktiengesellschaft1.191.320.81ONCBeigene0.051.931.72SMMTSummit TherapeuticsN/A8.318.31SSDOYShiseido0.301.080.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBAYRYBayer AktiengesellschaftN/AONCBeigene48.55%SMMTSummit Therapeutics4.61%SSDOYShiseido0.02%Insider OwnershipCompanyInsider OwnershipBAYRYBayer AktiengesellschaftN/AONCBeigene6.62%SMMTSummit Therapeutics88.30%SSDOYShiseidoN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBAYRYBayer Aktiengesellschaft99,7233.93 billionN/ANot OptionableONCBeigene9,00098.87 million90.59 millionN/ASMMTSummit Therapeutics110737.68 million86.28 millionOptionableSSDOYShiseido30,540399.66 millionN/ANot OptionableSSDOY, ONC, BAYRY, and SMMT HeadlinesRecent News About These Companies2024 Top 100: Shiseido Sees Stable Sales, Plummeting Operating ProfitApril 18, 2025 | msn.comShiseido Americas announces Interim CEO as Ron Gee resignsApril 17, 2025 | globalcosmeticsnews.comShiseido Americas CEO Ron Gee departs amid sales slowdownApril 16, 2025 | cosmeticsbusiness.comShiseido unveils mineral sun screen developmentApril 16, 2025 | globalcosmeticsnews.comAnnouncing the JLPGA Tour “Shiseido JAL Ladies Open”April 15, 2025 | breakingtravelnews.comShiseido Americas CEO ResignsApril 15, 2025 | beautypackaging.comRon Gee Departs Shiseido AmericasApril 15, 2025 | yahoo.comShiseido (OTCMKTS:SSDOY) Hits New 1-Year Low - Should You Sell?April 9, 2025 | marketbeat.comK-beauty fuels Shiseido’s global strategy: APAC chiefApril 6, 2025 | koreaherald.comShiseido (OTCMKTS:SSDOY) Shares Pass Below Fifty Day Moving Average - Should You Sell?April 6, 2025 | marketbeat.comShiseido’s ‘The Gift’ Pop-Up Brings Skincare Innovation to IONApril 4, 2025 | popspoken.comShiseido: Struggling To Regain MomentumApril 2, 2025 | seekingalpha.comHow to meet Win Metawin at the Shiseido ION Orchard Singapore pop-up on 3 AprilApril 1, 2025 | lifestyleasia.comShiseido merges travel retail and China operations to better respond to ‘volatile market conditions’April 1, 2025 | cosmeticsbusiness.comShiseido Merges China and Travel Retail OperationsMarch 31, 2025 | globalcosmeticsnews.comInterview: Shiseido Chief Brand Officer Echo Lo on why age really is just a numberMarch 30, 2025 | moodiedavittreport.comShort Interest in Shiseido Company, Limited (OTCMKTS:SSDOY) Drops By 46.6%March 29, 2025 | marketbeat.comShiseido combines China and Travel Retail businesses in restructure; Philippe Lesné to retire from roleMarch 29, 2025 | moodiedavittreport.comShiseido’s new Ultimune Power Infusion Serum commences travel retail roll-outMarch 6, 2025 | moodiedavittreport.comShiseido x Forbes: Potential Has No Age SummitMarch 6, 2025 | forbes.comCan Shiseido’s Ultimune Research Aid Cancer Prevention?March 6, 2025 | forbes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesInvestors Sell Microsoft Stock on OpenAI News—Time to Buy? By Chris Markoch | April 22, 2025View Investors Sell Microsoft Stock on OpenAI News—Time to Buy? Viking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsMarvell Gets Tariff Lifeline But Expect More VolatilityBy Chris Markoch | April 11, 2025View Marvell Gets Tariff Lifeline But Expect More Volatility 2 Reasons to Buy Apple Stock and 1 Significant RiskBy Chris Markoch | April 2, 2025View 2 Reasons to Buy Apple Stock and 1 Significant RiskGrocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsBy MarketBeat Staff | April 5, 2025View Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsSSDOY, ONC, BAYRY, and SMMT Company DescriptionsBayer Aktiengesellschaft OTCMKTS:BAYRY$6.61 +0.18 (+2.80%) As of 03:59 PM EasternBayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.Beigene NASDAQ:ONC$244.90 -11.26 (-4.40%) As of 04:00 PM EasternBeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Summit Therapeutics NASDAQ:SMMT$23.47 -13.23 (-36.05%) Closing price 04:00 PM EasternExtended Trading$24.31 +0.84 (+3.58%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Shiseido OTCMKTS:SSDOY$16.75 +0.43 (+2.60%) As of 03:50 PM EasternShiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
